# A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1

> **NCT03905694** · PHASE3 · COMPLETED · sponsor: **Alnylam Pharmaceuticals** · enrollment: 18 (actual)

## Conditions studied

- Primary Hyperoxaluria
- Primary Hyperoxaluria Type 1 (PH1)

## Interventions

- **DRUG:** Lumasiran

## Key facts

- **NCT ID:** NCT03905694
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-22
- **Primary completion:** 2020-06-29
- **Final completion:** 2024-07-26
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03905694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03905694, "A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03905694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*